Log In
Print
BCIQ
Print
Print this Print this
 

molidustat (BAY 85-3934)

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionHypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN) inhibitor
Molecular Target Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN)
Mechanism of ActionHypoxia-inducible factor prolyl hydroxylase inhibitor
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I
Standard IndicationAnemia
Indication DetailsTreat anemia; Treat anemia associated with chronic kidney disease (CKD); Treat anemia associated with end-stage renal disease
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today